These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11740191)

  • 1. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    van der Valk M; Kastelein JJ; Murphy RL; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato RK; Molhuizen HO; Reiss P;
    AIDS; 2001 Dec; 15(18):2407-14. PubMed ID: 11740191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    Negredo E; Ribalta J; Paredes R; Ferré R; Sirera G; Ruiz L; Salazar J; Reiss P; Masana L; Clotet B
    AIDS; 2002 Jul; 16(10):1383-9. PubMed ID: 12131215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Mankhatitham W; Luaengniyomkul A; Manosuthi W
    J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Lange JM
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of nevirapine on lipid metabolism.
    Clotet B; van der Valk M; Negredo E; Reiss P
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S79-84. PubMed ID: 14562862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    van Leth F; Hall DB; Lange JM; Reiss P
    HIV Med; 2006 Sep; 7(6):347-50. PubMed ID: 16903977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    Floridia M; Tamburrini E; Anzidei G; Tibaldi C; Guaraldi G; Guerra B; Meloni AM; Vimercati A; Molinari A; Pinnetti C; Dalzero S; Ravizza M;
    AIDS Patient Care STDS; 2009 Mar; 23(3):147-52. PubMed ID: 19866532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
    J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
    Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L;
    Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
    Franssen R; Sankatsing RR; Hassink E; Hutten B; Ackermans MT; Brinkman K; Oesterholt R; Arenas-Pinto A; Storfer SP; Kastelein JJ; Sauerwein HP; Reiss P; Stroes ES
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1336-41. PubMed ID: 19667106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    Fisac C; Virgili N; Ferrer E; Barbera MJ; Fumero E; Vilarasau C; Podzamczer D
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5186-92. PubMed ID: 14602748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
    Sankatsing RR; Wit FW; Pakker N; Vyankandondera J; Mmiro F; Okong P; Kastelein JJ; Lange JM; Stroes ES; Reiss P
    J Infect Dis; 2007 Jul; 196(1):15-22. PubMed ID: 17538878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.